Greifswald, 01/05/2021 - CHEPLAPHARM successfully closes acquisition of cardiovascular and metabolic portfolio from Takeda
Last week CHEPLAPHARM closed it’s largest acquisition so far, in terms of purchase price and volume. The acquisition from Takeda Pharmaceutical Company Limited includes a variety of branded products, targeting the therapeutic areas of cardiology, endocrinology, sleep disorders and gastrointestinal diseases. The products will be distributed mainly in the European markets.
"This transaction demonstrates our growing visibility and reputation as a global player in the pharmaceutical market. The portfolio contains high-quality branded products that are spread across multiple therapeutic areas, thus meeting our goal of maximum diversification," explains Sebastian Braun, CEO of CHEPLAPHARM.
In 2020, Cheplapharm was able to build on the success of previous years and achieved stable growth rates in many respects. These include, in particular, the number of new products and extensive investments in conjunction with a new, solid financing structure, the successful hiring of more than 100 new employees and the extension of an adjacent building to expand our company site in Greifswald.